We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Syros Pharmaceuticals Inc | NASDAQ:SYRS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.20% | 5.01 | 5.02 | 5.31 | 5.32 | 5.00 | 5.00 | 88,048 | 21:46:05 |
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference. Management will also be available for one-on-one meetings. Details are as follows:
TD Cowen 44th Annual Health Care Conference
Date: Tuesday, March 5 Panel Title: Novel Oncology Targets Panel Time: 9:10 a.m. ET Location: Boston Marriott Copley Place, Boston, MA
A live webcast of the panel discussion will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the live event.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARĪ± agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227887206/en/
Syros Contact Karen Hunady Director of Corporate Communications & Investor Relations 1-857-327-7321 khunady@syros.com Investor Contact Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com
1 Year Syros Pharmaceuticals Chart |
1 Month Syros Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions